10-K: Onconetix Plunges into Deeper Losses, Faces Nasdaq Delisting Amidst Strategic Pivot and Going Concern Doubts

Onconetix, Inc. reported a substantial net loss of $58.7 million for 2024, a significant working capital deficit, and explicit doubts about its ability to continue as a going concern, while abandoning its ENTADFI commercialization to focus on the Proclarix prostate cancer diagnostic.

Summary

• Onconetix, a commercial-stage biotechnology company, reported a net loss of $58.7 million for the fiscal year ended December 31, 2024, a significant increase from $37.4 million in 2023.
• The company had a working capital deficit of approximately $17.3 million and an accumulated deficit of $115.7 million as of December 31, 2024.
• Cash balance as of December 31, 2024, was approximately $0.6 million, and as of May 30, 2025, it was approximately $0.5 million, which management states is insufficient to fund operations through December 2025.
• Management explicitly stated 'substantial doubt about our ability to continue as a going concern' due to historical and expected operating losses and net operating cash flow deficits.
• The company has abandoned commercialization of its ENTADFI product due to time, resources, cash runway, and indebtedness, and is actively working with an investment advisor for its potential sale or other transaction.
• Current strategic focus is on commercializing Proclarix, an in vitro diagnostic test for prostate cancer, which is approved for sale in the European Union and licensed to LabCorp for U.S. development as a lab-developed test.
• Revenue for 2024 was $2.5 million, primarily attributable to Proteomedix (Proclarix sales and development services), a substantial increase from $58,465 in 2023.
• The company incurred significant impairment charges in 2024, including $32.3 million for goodwill and $10.3 million for intangible assets related to the Proteomedix acquisition, and $3.5 million for ENTADFI assets.
• Onconetix received multiple Nasdaq deficiency notices for non-compliance with minimum bid price rules ($1.00 and $0.10) and failure to timely file its 10-K and 10-Q reports, facing potential delisting.
• The company is pursuing a non-binding Letter of Intent for a potential business combination with Ocuvex Therapeutics, Inc., where pre-closing Ocuvex equity holders would own approximately 90% of the combined company.
• Material weaknesses in internal controls over financial reporting were identified as of December 31, 2024, including inadequate segregation of duties, ineffective risk assessment, and insufficient accounting resources.

Sentiment

Score: 2

Explanation: The company is in severe financial distress, with substantial doubt about its ability to continue as a going concern, significant accumulated deficits, and ongoing operating losses. Multiple Nasdaq delisting notices and the abandonment of a key product (ENTADFI) further highlight the precarious situation. While there's a strategic pivot to Proclarix and some capital raises, the funds are explicitly stated as insufficient, and the overall financial health is highly negative.

Positives

• Revenue increased significantly to $2.5 million in 2024, primarily from Proteomedix, compared to $58,465 in 2023, indicating initial commercial traction for Proclarix.
• Proclarix, the company's lead product, is approved for sale in the European Union under IVDR and has an exclusive license agreement with LabCorp for U.S. development, providing established market access channels.
• Clinical studies have confirmed Proclarix's high sensitivity (above 90%) and negative predictive value (greater than 90%) for clinically significant prostate cancer, suggesting strong diagnostic utility.
• Proclarix is included in the European Association of Urology (EAU) and American Urological Association/Society of Urologic Oncology (AUA/SUO) clinical guidelines, validating its clinical value and potentially accelerating payor adoption.
• The company has secured an Equity Line of Credit (ELOC) for up to $25.0 million, having drawn approximately $6.2 million as of May 30, 2025, providing some access to capital.
• The appointment of Karina M. Fedasz as Interim Chief Executive Officer and Interim Chief Financial Officer brings over two decades of experience in capital raising, M&A, and financial management.
• The Board of Directors possesses extensive expertise in life sciences, business, and finance, including individuals with CFO experience at publicly-traded pharmaceutical companies and venture capital backgrounds.

Negatives

• The company reported a substantial net loss of $58.7 million in 2024, an increase of 56.9% from $37.4 million in 2023.
• As of December 31, 2024, the company had a working capital deficit of approximately $17.3 million and an accumulated deficit of $115.7 million.
• Cash balance of $0.6 million as of December 31, 2024, and $0.5 million as of May 30, 2025, is insufficient to fund operations through December 2025, raising substantial doubt about its ability to continue as a going concern.
• The company abandoned commercialization of its ENTADFI product, leading to a full impairment of ENTADFI assets totaling $3.5 million in 2024 (following $14.7 million in 2023).
• Significant impairment charges of $32.3 million for goodwill and $10.3 million for intangible assets related to the Proteomedix acquisition were recorded in 2024.
• The company is non-compliant with Nasdaq listing standards (minimum bid price and timely filing of 10-K/10-Q reports) and faces potential delisting.
• Management determined that funds readily available under the existing ELOC will not be sufficient to sustain operations, indicating a continued capital shortfall.
• The company owes approximately $9.3 million in notes payable to Veru as of December 31, 2024, and may not have sufficient funds to meet these obligations.
• Material weaknesses in internal controls over financial reporting were identified, posing risks to financial reporting accuracy and fraud prevention.
• The potential Ocuvex business combination, if completed, would result in pre-closing Ocuvex equity holders owning approximately 90% of the combined company, indicating significant dilution for existing shareholders.
• The company has significant customer concentration, with 100% of development service revenue from Immunovia and 73% of product sales revenue from LabCorp in 2024, posing a risk if these relationships deteriorate.

Risks

• There is substantial doubt about the company's ability to continue as a going concern, requiring significant additional capital to fund operations and satisfy obligations.
• If the company is unable to raise additional capital when needed, it could be forced to delay, reduce, or terminate commercialization efforts or certain operations, potentially leading to bankruptcy.
• Shareholders may not realize a benefit from the ENTADFI or Proteomedix acquisitions commensurate with the ownership dilution experienced.
• The company may fail or elect not to commercialize Proclarix, or experience significant delays, which would prevent profitability.
• Proclarix is subject to intense competition from other prostate cancer diagnostics and larger, well-established companies with substantially greater resources.
• The company is entirely dependent on third parties, including LabCorp, for the development, marketing, distribution, and sale of Proclarix, and has no internal manufacturing capabilities.
• Inability to gain and retain market acceptance for Proclarix by healthcare providers, patients, and payors could limit revenue generation.
• The product could be subject to marketing restrictions or withdrawal from the market, and the company may face penalties for non-compliance with regulatory requirements.
• The company owes a significant amount of money to Veru ($9.3 million in notes payable as of Dec 31, 2024), which it does not currently have, potentially leading to legal action.
• It is difficult and costly to protect proprietary rights, and the patent position may not adequately protect products, allowing competitors to enter the market.
• The market price of the common stock has been extremely volatile and may continue to be highly volatile, leading to potential loss of investment for stockholders.
• There is no assurance that the company will be able to comply with Nasdaq's continued listing requirements, risking delisting and adverse consequences for stock liquidity.
• A possible short squeeze due to a sudden increase in demand for common stock that largely exceeds supply may lead to extreme price volatility.
• The company may have violated Section 13(k) of the Exchange Act (personal loans to former executives) and may be subject to sanctions.
• Failure to maintain proper and effective internal controls, with identified material weaknesses, could impair the ability to produce accurate financial statements and prevent fraud.
• Misconduct and errors by current and former employees and third-party service providers could cause a material adverse effect on the business and reputation.
• The potential Ocuvex Business Combination may not achieve its intended results, could lead to unanticipated liabilities, and will incur significant transaction costs.
• The issuance or conversion of securities (e.g., through ELOC or Ocuvex transaction) would result in significant dilution in the equity interest of existing shareholders.
• Security threats to information technology infrastructure and/or physical buildings could expose the company to liability and damage its reputation and business.
• The company's future success depends on its ability to attract, retain, and motivate qualified personnel, which is challenging in a competitive industry.
• Inadequate funding for regulatory agencies (FDA, SEC) could hinder timely review of regulatory submissions, impacting business operations.
• Macroeconomic pressures, natural disasters, pandemics, and man-made problems could disrupt business operations and financial capacities.
• The industry is subject to rapid change, which could make the company's solutions and diagnostic tests obsolete if it fails to innovate continuously.
• Cost-containment efforts by customers, purchasing groups, and governmental organizations could have a material adverse effect on future sales and profitability.
• Reliance on government funding and collaboration with government entities may impose requirements that increase development, commercialization, and production costs.
• The company is subject to U.S. and foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws, with potential for criminal liability for violations.

Future Outlook

The company anticipates continued significant expenses for the foreseeable future as it commercializes Proclarix. It expects to finance future cash needs through public or private equity or debt financings, third-party funding, and strategic arrangements until significant revenue is generated. There is substantial doubt about the company's ability to continue as a going concern, and if unable to secure additional capital, it may be forced to curtail or terminate operations. The company is also pursuing a potential non-binding business combination with Ocuvex Therapeutics, Inc., which, if completed, would result in Ocuvex equity holders owning approximately 90% of the combined entity.

Management Comments

• "Our current cash balance is not sufficient to fund operations through the end of December 2025."
• "Management also intends to secure additional required funding through equity or debt financings if available, and to utilize the ELOC entered into in October 2024... to assist with the paydown of notes issued to Veru and to fund current operating needs."
• "However, based on the terms of the ELOC and the current maximum availability, management determined that the funds readily available under the ELOC will not be sufficient to sustain operations."
• "If the Company is unable to secure additional capital, it may be required to curtail any future clinical trials, development, and/or commercialization of future product candidates, and it may take additional measures to reduce expenses in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations, or, if it is required to, file for bankruptcy."
• "The Panels decision about the stay request is still pending as of the date these financials were filed. However, there are no assurances that the Panel will grant the Companys request for continued listing or an extension to demonstrate compliance."
• "We believe that the extreme volatility we experienced in recent periods reflects market and trading dynamics unrelated to our underlying business, our actual or expected operating performance, our financial condition, or macro or industry fundamentals, and we do not know if these dynamics will continue or how long they will last. Under these circumstances, we caution you against investing in our common stock, unless you are prepared to incur the risk of losing all or a substantial portion of your investment."

Industry Context

The molecular diagnostics field is intensely competitive, characterized by rapid technological changes, frequent new product introductions, and industry consolidation. The prostate cancer diagnostic market, which Onconetix's Proclarix targets, faces challenges with PSA test overdiagnosis, leading to unnecessary biopsies. Proclarix aims to address this unmet medical need. The global in vitro diagnostic (IVD) market was valued at $101 billion in 2024, with significant demand in developed economies. Evolving regulatory frameworks, such as the EU's IVDR, are introducing stricter compliance standards, which Proclarix has met early, potentially offering a competitive advantage over less compliant products.

Comparison to Industry Standards

• Proclarix is positioned against existing prostate cancer diagnostic tests such as %fPSA, 4Kscore (OPKO Health, Inc.), phi score (Beckman Coulter, Inc.), PCA3 (Gen-Probe Inc./Hologic, Inc.), SelectMDx (MdxHealth SA), and ExoDx IntelliScore (Exosome Diagnostics, Inc./Bio-Techne Corporation).
• The document claims Proclarix demonstrates 'comparable or often superior clinical performance' to these tests, highlighting its blood-based, minimally invasive nature and high reproducibility as competitive advantages.
• Clinical studies suggest Proclarix is effective before, after, and in combination with MRI assessment, outperforming PSA density in selecting appropriate candidates for prostate biopsy, particularly in cases with indeterminate MRI results.
• Inclusion of Proclarix in the European Association of Urology (EAU) and American Urological Association/Society of Urologic Oncology (AUA/SUO) clinical guidelines signifies a strong validation of its clinical utility and importance, aligning with recognized medical standards.
• The company emphasizes that Proclarix's CE marking under the new IVDR (Class C device) makes it 'one of the first IVDs under the new EU regime,' suggesting a higher quality standard and potential market access advantage over competitors still operating under older directives or without CE mark.
• No specific financial or operational benchmarks (e.g., revenue per employee, R&D spend as % of revenue, profit margins) are provided for direct quantitative comparison to named competitors like OPKO Health, Beckman Coulter, Bio-Techne, or MdxHealth SA.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal proceedings.
• WraSer has indicated it may seek damages from the company due to the termination of the WraSer APA and WraSer MSA, following the company's determination of a Material Adverse Effect and subsequent termination notice.

Related Party Transactions

• During 2022 and the first three quarters of 2023, the company paid personal expenditures of its former CEO and an accounting employee (former CEO's assistant) on corporate credit cards, totaling approximately $363,000. These amounts were not anticipated to be recovered and were fully reserved.
• On January 23, 2024, the company issued a non-convertible debenture in the principal amount of $5.0 million to Altos Ventures (PMX Investor), a related party and 5% stockholder. This debenture, including accrued interest, was later settled through the issuance of shares on September 24, 2024.
• Thomas Meier, a Board member appointed on February 6, 2024, provides consulting services to Proteomedix, with approximately $58,000 in related expenses recorded during the year ended December 31, 2024.

Stakeholder Impact

• **Shareholders**: Face significant dilution from past and potential future equity raises (ELOC, Ocuvex transaction), substantial doubt about the company's ability to continue as a going concern, potential loss of investment, highly volatile stock price, and risk of delisting from Nasdaq. No cash dividends are anticipated in the foreseeable future.
• **Employees**: Experienced termination of three ENTADFI program employees in April 2024, and three Proteomedix employees were given notice of employment termination effective July 31, 2025. There is a risk of further workforce reductions if additional capital is not secured.
• **Creditors (e.g., Veru)**: The company owes significant amounts, including approximately $9.3 million in notes payable to Veru as of December 31, 2024, and may be unable to meet these obligations, potentially leading to legal action and enforcement of rights.
• **Customers (e.g., LabCorp, Immunovia)**: High customer concentration means that the loss of a major customer could severely impact revenue. Potential for disruptions if the company's financial instability affects product supply or service quality.
• **Suppliers/Manufacturers**: The company's reliance on single-source suppliers and third-party manufacturers creates a risk of supply interruptions if the company faces financial difficulties or if these suppliers fail to meet their obligations, potentially impacting product availability.

Next Steps

• Continue negotiations to enter into a definitive agreement for the potential business combination with Ocuvex Therapeutics, Inc.
• Seek significant additional capital through equity or debt financings, third-party funding, and strategic arrangements to sustain operations.
• Implement and remediate identified material weaknesses in internal controls over financial reporting.
• Address Nasdaq listing deficiencies (minimum bid price, late filings) to avoid delisting.
• Continue commercialization efforts for Proclarix in Europe and support LabCorp's development and commercialization in the U.S.
• Work with an investment advisor to assist with the potential sale or other transaction of the ENTADFI assets.
• Complete the exchange of Proteomedix Stock Options into Onconetix restricted stock units.
• Manage and meet existing and future contractual commitments and obligations, including remaining payments due to Veru.

Key Dates

Recommendation

Keywords

Biotechnology, Prostate Cancer, Diagnostics, Proclarix, SEC Filing, 10-K, Financial Reporting, Going Concern, Nasdaq Delisting, Capital Raise, Proteomedix, LabCorp, ENTADFI, Corporate Governance, Internal Controls, Risk Management, Oncology, Men's Health